Prenuvo operates a whole-body MRI screening service designed for preventative health screening. Founded in 2018, the company has completed over 100,000 scans for more than 170,000 patients using proprietary hardware and software combined with AI-powered analysis. Each scan captures 1.3 billion data points to screen for hundreds of conditions across major organ systems, with the examination completed in under an hour without radiation or contrast agents. Approximately one in twenty scans yields a potentially life-saving finding.
The company employs more than 200 healthcare professionals, including radiologists, MRI technologists, and preventative health physicians. Its technical capabilities span magnetic resonance imaging hardware optimization, medical imaging, proprietary software development, artificial intelligence, and data analytics. Prenuvo has raised $120 million in Series B funding and operates across North America and the United Kingdom, with plans for further international expansion.
Prenuvo's operating model emphasises proactive rather than reactive healthcare. The service targets individuals seeking to identify health conditions before symptoms emerge, positioning preventative screening as a core clinical offering rather than an ancillary service.
